Novo Nordisk A/S vs Pfizer: Business Model & Financial Comparison 2026
Novo Nordisk A/S · Healthcare / Drug Manufacturers - General·Pfizer · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | NVONovo Nordisk A/S | PFEPfizer |
|---|---|---|
| Market Cap | $169.56B | $152.73B |
| Revenue (TTM) | $309.06B | $62.58B |
| Revenue Growth | -7.6% | -1.2% |
| Gross Margin | 82.4% | 75.8% |
| Operating Margin | 44.5% | 23.9% |
| Net Margin | 33.1% | 12.4% |
| Return on Equity | 60.7% | 8.9% |
| P/E (Trailing) | 10.7x | 19.8x |
| P/E (Forward) | 11.4x | 9.5x |
| Free Cash Flow | $376.9M | $13.43B |
| Cash | $26.96B | $13.60B |
| Total Debt | $130.96B | $67.65B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Novo Nordisk A/S
Novo Nordisk A/S stands as a leading company in Healthcare. Generating $309.06 billion in annual revenue (growing -7.6% year-over-year) and carrying a market capitalization of $173.66 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Novo Nordisk A/S continues to execute on a multi-year strategic vision that balances growth inv…
Full Novo Nordisk A/S analysis →Pfizer
Pfizer Inc. stands as a leading company in Healthcare. Generating $62.58 billion in annual revenue (growing -1.2% year-over-year) and carrying a market capitalization of $151.30 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Pfizer Inc. continues to execute on a multi-year strategic vision that balances growth investment wit…
Full Pfizer analysis →SWOT Analysis Comparison
Strengths
Novo Nordisk A/S
- With a market capitalization of $173.66B, Novo Nordisk A/S is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access tha
- Novo Nordisk A/S's gross margin of 82.4% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.5% demonstrates disc
- A return on equity of 60.7% demonstrates that Novo Nordisk A/S generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Pfizer
- With a market capitalization of $151.30B, Pfizer Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that sma
- Pfizer Inc.'s gross margin of 75.8% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 23.9% demonstrates disciplin
- Pfizer Inc. generated $13.43B in free cash flow, providing financial flexibility to invest in growth initiatives, return capital to shareholders, or strengthen the balance sheet.
Weaknesses
Novo Nordisk A/S
- Novo Nordisk A/S's debt-to-equity ratio of 67.5 indicates meaningful financial leverage. Total debt stands at $130.96B against $26.96B in cash and equivalents.
- Year-over-year revenue declined 7.6%, raising questions about demand for Novo Nordisk A/S's core offerings and requiring management to articulate a credible recovery path.
Pfizer
- Pfizer Inc.'s debt-to-equity ratio of 78.0 indicates meaningful financial leverage. Total debt stands at $67.65B against $13.60B in cash and equivalents.
- Year-over-year revenue declined 1.2%, raising questions about demand for Pfizer Inc.'s core offerings and requiring management to articulate a credible recovery path.
Opportunities
Novo Nordisk A/S
- Novo Nordisk A/S operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in thi
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Novo No
- With $26.96B in cash and strong free cash flow generation, Novo Nordisk A/S is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Pfizer
- Pfizer Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this env
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Pfizer
- With $13.60B in cash and strong free cash flow generation, Pfizer Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Threats
Novo Nordisk A/S
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Novo Nordisk A/S's revenue is not fully insulated from macroeconomic cycles, and a recession
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Novo Nordisk A/S's
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Pfizer
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pfizer Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scen
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pfizer Inc.'s busin
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolNovo Nordisk A/S vs Pfizer: FAQ
- Is Novo Nordisk A/S bigger than Pfizer?
- By market capitalization, Novo Nordisk A/S is larger at $169.56B vs Pfizer's $152.73B.
- Which has better profit margins — Novo Nordisk A/S or Pfizer?
- Novo Nordisk A/S has higher net profit margins (33.1%) compared to Pfizer (12.4%). Gross and operating margins are compared in the table above.
- What sectors do Novo Nordisk A/S and Pfizer operate in?
- Novo Nordisk A/S operates in the Healthcare sector (Drug Manufacturers - General). Pfizer operates in the Healthcare sector (Drug Manufacturers - General).
- How does Novo Nordisk A/S's revenue compare to Pfizer's?
- Novo Nordisk A/S generates $309.06B in annual revenue (TTM) while Pfizer generates $62.58B. Novo Nordisk A/S is the larger company by revenue as of 2026.